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Abstract
Methamphetamine (Meth) is a widely abused stimulant and its users are at increased risk for multiple infectious diseases. To
determine the impact of meth on the immune system, we utilized a murine model that simulates the process of meth
consumption in a typical addict. Our phenotypic analysis of leukocytes from this dose escalation model revealed that meth
affected key immune subsets. Meth administration led to a decrease in abundance of natural killer (NK) cells and the
remaining NK cells possessed a phenotype suggesting reduced responsiveness. Dendritic cells (DCs) and Gr-1high
monocytes/macrophages were also decreased in abundance while Gr-1low monocytes/macrophages appear to show signs
of perturbation. CD4 and CD8 T cell subsets were affected by methamphetamine, both showing a reduction in antigen-
experienced subsets. CD4 T cells also exhibited signs of activation, with increased expression of CD150 on CD226-expressing
cells and an expansion of KLRG1+, FoxP32 cells. These results exhibit that meth has the ability to disrupt immune
homeostasis and impact key subsets of leukocytes which may leave users more vulnerable to pathogens.
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Introduction
Methamphetamine (Meth) is a highly addictive psychostimulant
and neurotoxicant of increasing popularity among drug-abusing
populations worldwide [1–9]. This rising popularity has significant
economic consequences, as in the US alone, the financial burden
of meth use was calculated at .23 billion dollars annually [10].
Meth is typically administered nasally, intravenously or orally, and
meth users experience feelings of euphoria, hyperactivity, reduced
appetite, sleeplessness, and arousal after administration [11]. After
injection, meth, a lipid-soluble monamine, has been shown to
disseminate and accumulate widely throughout tissues in both
humans and rats [12,13], and there is an extensive body of data
that describes the toxic effects of meth on the CNS and resulting
neurologic damage and cognitive impairment [14,15]. Meth users
are prone to increased rates of several types of infections, including
human immunodeficiency virus (HIV), hepatitis A, B, and C, and
methillicin-resistant Staphylococcus aureus, due to their involvement
in risky sexual practices and from the inherent dangers associated
with intravenous drug use [16–23]. In addition to these behaviors
putting users at increased risk of transmission of infectious agents,
meth has been shown to promote HIV infection of human
macrophages and increase hepatitis C replication within hepato-
cytes [24,25].
Meth itself is an immunomodulatory substance with a wide
range of effects that have been observed in diverse in vitro systems
as well as murine and nonhuman primate models. Several lines of
evidence support the notion that meth suppresses the immune
system. Meth has been associated with reduced leukocyte pro-
liferation [26–28], reduced IL-2 production [28–30], reduced
immunoglobulin production [30,31], and reduced macrophage
and dendritic cell (DC) function [32–34]. Meth also promotes
susceptibility to viral and fungal pathogens among hosts
[27,34,35]. While meth appears to suppress the response of B
and T cells, macrophages, and DCs, studies have shown that
natural killer (NK) cells exhibit increased levels of activation after
meth exposure [29,30,35,36], although at least one study reported
reduced NK cell function [37]. Meth has also been observed to
alter immune function in the brain, with increased microglia
activation and abundance after meth exposure [38]. Finally, meth
has been reported to promote apoptosis in the thymus and spleen
[39], as well as among cultured T cells [28].
Taken together, these studies reveal that meth has the ability to
profoundly interfere with immunological networks, affecting
diverse leukocyte subsets and thereby leaving the user vulnerable
to pathogens. Although several studies on meth have employed
flow cytometry to evaluate the immune response, this has not been
performed in a comprehensive manner to elucidate specific
cellular alterations induced by meth. Indeed, multiparameter flow
cytometry can be used to generate a detailed analysis of the
expression level of multiple proteins at the single cell level. This
allows the investigator to generate a complex, yet more complete,
picture of immunological networks in states of health, disease, and
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toxicant exposure, and ultimately produce a wealth of observations
to guide further investigations. As previous studies suggested
profound and detrimental impacts of meth on T cell, NK cell, and
macrophage/DC responses, we hypothesized that these deficien-
cies would result in specific phenotypic alterations of these cells,
thereby suggesting altered functionality in vivo. To explore this
hypothesis, we treated C57BL/6 mice with levels of methamphet-
amine that simulate usage patterns observed in typical human
addicts (following methods in [34]) and then examined multiple
leukocyte subsets to observe how meth changes the phenotypic
appearance of immune cells. Our results reveal that meth
treatment reduces the overall abundance of activated/antigen-
experienced CD4 and CD8 T cells while promoting activation and
expansion of discrete CD4 T cell subsets. We also observed that
meth impacts splenic myeloid cells, reducing the number of DCs
and Gr-1high monocytes/macrophages, while promoting the
perturbation of Gr-1low monocytes/macrophages. Finally, we
observed that meth contributes to a reduction in number of
splenic NK cells and leaves the majority of remaining NK cells
with a phenotype suggesting reduced responsiveness and func-
tional efficacy.
Methods
Mice and Meth Treatment
Male C57BL/6 mice 12–14 weeks of age were purchased from
Jackson Labs, housed in specific pathogen free conditions, and
given unlimited access to food and water. We purchased (+)-
methamphetamine hydrochloride from Sigma-Aldrich and em-
ployed a treatment regimen similar to that described in [34] that
simulates meth usage patterns of typical human addicts. Meth was
administered via intraperitoneal injections in a ramped dosing
schedule on days 1–4 with 2, 4, 6, and 8 mg/kg given per day. On
days 5–14, we plateaued the dosage to 10 mg/kg/day. Control
mice were given saline solution (vehicle) over this same time
period. On day 14, within 3 hours of the final injection, mice were
anesthetized with isofluorane and euthanized via cervical disloca-
tion. The Institutional Animal Care and Use Committee of the
University of Nebraska Medical Center approved all procedures.
Flow Cytometry
Spleens and mesenteric lymph nodes were harvested from
freshly euthanized mice. These were then teased apart with fine
forceps and ran through nylon mesh screens to produce single cell
suspensions. Red blood cells (RBCs) were removed from
splenocyte preparations by utilizing ammonium chloride RBC
lysis buffer. Prior to labeling cells with antibodies, we stained cells
with Live/Deadß Fixable.
Blue Dead Cell Stain (Life Technologies) and then blocked Fc
receptors using unlabeled, irrelevant rat IgG. We used mouse
monoclonal antibodies from multiple sources in our flow
cytometry panels. From BD Pharmingen, we utilized B220(RA3-
6B2), CD3e(500A2), CD11c(HL3), CD27(LG.3A10), CD44(IM7),
CD80(16-10A1), and NKp46(29A1.4). From eBiosciences, we
used CD4(GK1.5), CD8(53-6.7), CD11b(M1/70), CD25(PC61.5),
CD62L(MEL-14), CD94(18d3), CD86(GL-1), Gr-1(RB6-8C5),
NKG2D(CX5), FoxP3(FJK-16s), MHC II(M5/114.15.2), Ly-
49H(3D10) and Ly-49G2(eBio4D11). Antibodies against
CD3(17A2), CD27(LG.3A10), CD45RB(C363-16A),
KLRG1(2F1/KLRG1), CD150(TC15-12F12.2), and
CD226(10E5) were purchased from BioLegend. For surface
staining, cells were suspended in staining buffer consisting of
phosphate buffered saline (PBS) containing 0.5% bovine serum
albumin (BSA) and 0.05% sodium azide (NaN3). Surface-stained
cells were fixed in 1.5% paraformaldehyde (PFA) for 1 hour, then
washed and resuspended in staining buffer prior to analysis. For
FoxP3 staining, we used FoxP3 Fixation/Permeabilization Con-
centrate and Diluent from eBiosciences according to the
manufacturer’s recommendations. Cells were analyzed with an
LSR II (BD Biosciences) within 24 hours of preparation.
Analysis and Statistics
We used FlowJo (v. 8.8.6, TreeStar, Inc.) to analyze flow
cytometry data. Values from FlowJo were transferred into
GraphPad Prism (v. 4.0, GraphPad Software) for statistical
analysis. To test for significant differences between meth-treated
and control animals, we utilized the Mann-Whitney U Test.
Results
Meth Causes a Reduction in Absolute Number and
Proportion of Splenic Natural Killer Cells, Gr-1(Ly-6C)high
Monocytes/macrophages, and DCs
To determine the impact of meth exposure on the proportion
and number of splenic leukocyte subsets, we prepared splenocyte
preparations for flow cytometric analysis with antibodies against
CD3, B220, Gr-1, CD11b, CD11c, MHC II, and NKp46,
allowing us to define and quantify T cells, B cells, natural killer
(NK) cells, neutrophils, eosinophils, dendritic cells (DCs), and Gr-
1high and Gr-1low monocytes/macrophages (see gating strategy
Fig. 1 and Table 1). The Gr-1 antibody (clone RB6-8C5) binds to
epitopes on Ly-6G and Ly-6C [40], and can be used to label
neutrophils (SSCmed, Gr-1bright (co-expressing both Ly6G and
Ly6C at high levels)) and divide splenic monocytes/macrophage
into Gr-1high/low subsets, corresponding to high or low levels of
Ly-6C expression [41,42]. NKp46 is an activating receptor
specifically expressed by the NK cell lineage and can be used to
effectively label these cells [43].
Our results indicated that although absolute counts of total
splenocytes were not different between meth-treated and control
groups (Fig. 2A), meth treatment caused significant decreases in
proportion (data not shown) and number of NK cells (p = 0.003),
Gr-1(Ly-6C)high monocytes/macrophages (p = 0.0041), and DCs
(p = 0.0015) in meth-treated mice (Fig. 2B–D). T cells, B cells,
neutrophils, eosinophils, and Gr-1(Ly-6C)low monocytes/macro-
phages exhibited no significant difference in proportion or
absolute number after meth treatment (data not shown). These
results show that meth has the ability to negatively impact the
abundance of innate immune subsets.
Meth Treatment Causes the Perturbation of Gr-1(Ly-
6C)low Monocytes/macrophages
Meth treatment has been shown to upset antigen presentation
pathways and promote apoptosis, thus suggesting an alteration of
antigen presenting cell (APC) activation with meth treatment. To
investigate the role of meth treatment on APC and APC-precursor
activation levels, we labeled splenic DCs and monocytes/
macrophages with antibodies against the costimulatory markers
CD80 and CD86 [44], and then examined surface protein
expression by flow cytometry. Interestingly, Gr-1low monocytes/
macrophages showed statistically significant upregulation of CD80
(p = 0.0057; measured by mean fluorescence intensity (MFI)), but
not CD86 (data not shown), after meth exposure (Fig. 3A & B).
This increase in CD80 expression was coupled with a decrease in
CD11b expression by Gr-1low monocytes/macrophages
(p = 0.0004; Fig. 3C & D). There was no change in CD80 or
CD86 expression levels by Gr-1high monocytes/macrophages and
Meth Administration Induces Immune Alterations
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DCs (data not shown). An upregulation in CD80 in parallel with
a downregulation of CD11b suggests that that Gr-1low monocytes/
macrophages are perturbed after meth treatment, while Gr-1high
monocytes/macrophages appear to be less sensitive to meth-
induced activation.
A Greater Proportion of NK Cells Possess a Phenotype
Suggesting Terminal Differentiation After Meth Exposure
Meth treatment has been shown to both promote and inhibit
NK cell activation. To address if NK cells exhibit an altered
phenotype suggesting changes in maturation or development, we
labeled NK cells (NK1.1+, CD42, CD82) with KLRG1, CD27,
Ly-49H, Ly-49G2 and CD94. Among murine NK cells, CD27
Figure 1. Gating strategy for defining major subsets of leukocytes among splenocytes. A. Dead cells were removed from the analysis
using Live/DeadH fixable dead cell stain. B. Doublets were removed from living cells (Live/Dead2) using FSC-A and FSC-H. C. Gr-1bright splenocytes
were gated and defined as neutrophils. D. NKp46+ events were gated from Gr-1low/2 splenocytes and defined as natural killer (NK) cells. E. NKp462,
Gr-1low/2 splenocytes were divided into MHC II+ and MHC II2 populations. F. MHC II+ events were split by B220 and CD11c expression. MHC II+,
B220+, CD11c2 events were defined as B cells. MHC II+ B2202, CD11c+ events were defined as dendritic cells (DCs). G.We split MHC II2 events by CD3
and CD11b expression. CD11b-, CD3+, MHC II- events were labeled as T cells. H. CD11b+, CD32, MHC II- events were split according to SSC profile.
Events with higher SSC values (suggesting greater internal granularity) were labeled as eosinophils. I. Events with lower SSC values were divided by
Gr-1 expression, giving two populations: Gr-1(Ly-6C)high monocytes/macrophages and Gr-1(Ly-6C)low monocytes/macrophages (mono/MW).
doi:10.1371/journal.pone.0049897.g001
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expression is associated with naı̈ve status of NK cells and KLRG1
expression is associated with terminal differentiation [45,46]. We
noticed a significant decrease in proportion of KLRG12, CD27+
NK cells (p = 0.0011) concurrent with a significant increase in
KLRG1+, CD272 NK cells (p = 0.0002; Fig. 4A–C). While
a greater proportion of NK cells possessed a terminally differen-
tiated phenotype, this did not correspond to an overall increase in
number. We observed that total KLRG1+, CD272 NK cells were
relatively similar between meth-treated and control animals
(Fig. 4E). However, there was a significant decrease in total
KLRG12, CD27+ NK cells after meth treatment compared to
control (p,0.0001; Fig. 4D). These results suggest that meth
treatment may promote the terminal differentiation of NK cells
and also reduce the abundance of non-terminally differentiated
Table 1. Phenotype of splenic leukocyte subsets analyzed after meth treatment.
Leukocyte subset Surface expression of relevant phenotypic markers
T cells CD3+, MHC II2, Gr-12, NKp462, CD11b2
B cells B220+, MHC II+, CD32, Gr-12, NKp462, CD11c2
Natural killer (NK) cells NKp46+, Gr-12, MHCII2, CD32
Dendritic cells (DCs) CD11c+, MHC II+, CD11b+/2, CD32, B2202, NKp462
Neutrophils CD11b+, Gr-1bright, SSCmed, CD32, B2202, CD11c2, MHCII2, NKp462
Eosinophils CD11b+, Gr-1low, SSChigh, CD32, B2202, CD11c2, MHCII2, NKp462
Gr-1(Ly-6C)high mono/MW CD11b+, Gr-1+, MHCII2, CD32, B2202, CD11c2, NKp462
Gr-1(Ly-6C)low mono/MW CD11b+, Gr-12, MHCII2, CD32, B2202, CD11clow/2, NKp462
doi:10.1371/journal.pone.0049897.t001
Figure 2. Meth causes a reduction of splenic leukocyte subsets. C57BL/6 mice were treated with vehicle (control) or ramped dosage of
methamphetamine (meth – see methods) for 14 days. At day 14, mice were sacrificed and splenic leukocyte subsets were analyzed by flow cytometry.
A. Meth treatment did not alter total splenocyte number. B. Meth causes a significant reduction in total natural killer (NK) cells (NKp46+, CD32,
B2202, Gr-12, MHC II2). C. Gr-1high monocytes (CD11b+, Gr-1high, MHC II2, CD32, B2202) were reduced after meth treatment. D. Meth treatment
reduces dendritic cells (DCs) defined as CD11c+, MHC II+, B2202, Gr-12 events. Dead cells and doublets were removed prior to analysis. **P,0.01
calculated by Mann-Whitney U Test. Bars represent mean. Data are from 2 experiments of 5 animals per treatment group per experiment.
doi:10.1371/journal.pone.0049897.g002
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NK cells. No difference in Ly-49H, Ly-49G2, or CD94 expression
was noted after treatment (data not shown).
CD4 T Cells
Meth treatment results in decreased proportions of
activated CD4 T cells in spleen and lymph node. Meth
has been associated with altered T cell activation and proliferation.
We investigated the role of meth on CD4 and CD8 T cells in the
spleen and mesenteric lymph node (MLN) to determine if meth
influences antigen-experienced and naı̈ve subsets of T cells in vivo.
Within the splenic CD4 T cell compartment, we observed
a significant decrease in proportion of CD62Llow, CD44high
antigen-experienced cells after meth treatment (p,0.0001; Fig. 5A
& B). Futhermore, within this CD62Llow, CD44high subset we
observed a decreased proportion of cells expressing high levels of
CD27 in meth-treated mice compared to controls (p = 0.0029;
Fig. 5C & D). Among CD62L+ CD4 T cells, we observed
a significant increase in proportion of naı̈ve CD45RBbright,
CD44low cells (p,0.0001), with significant decreases in proportion
of CD45RBlow, CD44low (p = 0.0003) and CD45RBlow, CD44high
cells (p = 0.0001; Fig. 6A–D). Combined, these results suggest
a decrease in overall activation/antigen experience by CD4 T
cells. While a similar decrease in CD62L2, CD44high proportion
was noted in the MLN (p= 0.0052; Fig. 7A & B), we did not
observe differences in CD27 expression within this subset in this
organ (data not shown). We also observed no differences in the
CD62L+ population of MLN CD4 T cells after meth treatment
(data not shown). In total, meth appears to inhibit CD4 T cell
activation in secondary lymphoid tissue.
Meth causes upregulation of CD150 (SLAM) on CD226+
CD4 T cells. Members of the signaling lymphocytic activation
(SLAM) family are associated with T cell activation, and signaling
through CD150 (SLAM) results in IFN-c production, differenti-
ation, and proliferation by T cells [47]. CD226 expression has
been associated with Th1 status in murine T cells [48]. We
hypothesized that meth’s negative impact on T cell activation
should correspond to a decrease in CD150 expression as well as
a decreased proportion of CD226-expressing CD4 T cells. To test
this hypothesis, we compared CD150 MFI and proportion of
CD226+ CD4 T cells from meth-treated and control mice.
Figure 3. Meth perturbs Gr-1low monocytes/macrophages. Gr-1low monocytes/macrophages were analyzed for signs of activation after meth
treatment using flow cytometry. A. Representative histogram showing CD80 (B7-1) expression by Gr-1ow monocytes/macrophages. Red represents
a meth-treated animal, black represents a vehicle-treated animal, and grey is the isotype control. B. Meth causes increased expression of CD80 by Gr-
1low, quantified by mean fluorescence intensity (MFI). C. Representative histogram showing CD11b (Mac-1) expression by Gr-1low monocytes/
macrophages with colors as in A above. D. Meth causes decreased expression of CD11b by Gr-1low monocytes, quantified by MFI. Dead cells and
doublets were removed prior to analysis. **p,0.01, ***p,0.001 calculated by Mann-Whitney U Test. Error bars represent SEM. Data are from 2
experiments of 5 animals per treatment group per experiment.
doi:10.1371/journal.pone.0049897.g003
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Although we observed no differences in CD226 expression after
meth treatment (data not shown), we did observe significantly
increased expression of CD150 on CD226+ CD44+ CD4 T cells
(p,0.0001; Fig. 8A & B). The upregulation of this costimulatory
molecule suggests that meth promotes the activation of specific
subsets of CD4 T cells.
Meth causes the expansion of a KLRG1+ CD4 T cell subset
that is not FoxP3+. Regulatory T cells (TREGS) are fundamental
in maintaining tolerance [49] and within the TREG population,
a potent regulatory compartment expressing KLRG1 has been
reported in healthy mice [50]. To determine the effect of meth on
specific subsets of TREGs, we labeled splenic CD4 T cells with
FoxP3, CD25 (IL-2Ra), and KLRG1, with additional markers of
homing and differentiation. Although we observed no significant
difference in KLRG1+/2, FoxP3+, CD25+ CD4 T cells after meth
treatment (data not shown), we did observe a significant expansion
of KLRG1+ FoxP32 CD4 T cells in proportion and absolute
number after meth treatment (p,0.0001; Fig. 9A & B). These cells
were CD44high, CD45RBlow, CD25low CD62Llow, and NKG2D2
(data not shown), a profile of protein expression suggesting
Figure 4. Meth alters NK cell subsets. We labeled splenic NK cells (NK1.1+, CD42, CD82) with antibodies against killer cell lectin-like receptor G1
(KLRG1) and CD27 to determine if meth treatment alters functionally distinct NK cell subsets. A. Representative gating showing KLRG1 and CD27 on
gated NK cells. B and C. Meth treatment results in a decreased proportion of KLRG12, CD27+ NK cells with an increase in proportion of KLRG1+,
CD272 NKs. D and E. Although proportionally higher, KLRG1+, CD272 NK cells are not increased in absolute number. However, KLRG12, CD27+ NK
cells were significantly reduced in number. Dead cells and doublets were removed prior to analysis. ***p,0.001 calculated by Mann-Whitney U Test.
Bars represent mean. Data are from 2 experiments of 5 animals per treatment group per experiment.
doi:10.1371/journal.pone.0049897.g004
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activation. A similar KLRG1+ expansion was observed in MLN,
although FoxP3 staining was not performed in the MLN (data not
shown). These data from spleen and MLN demonstrate that meth
promotes the expansion of a CD4 T cell subset with a terminal
effector phenotype, an unexpected find amidst signs of suppres-
sion.
CD8 T Cells
Meth treatment results in decreased proportions of
activated CD8 T cells in spleen and lymph node. Naı̈ve
CD8 T cells can differentiate into cytotoxic effectors with short-
lived status or long-term memory potential. Since meth-induced
deficiencies in these effector subsets may leave the user more
vulnerable to pathogens, we investigated meth’s ability to alter
CD8 T cell subpopulations. CD8 T cells can be divided into 4
subsets depending on levels of CD62L and CD44 expression:
CD62Lhigh, CD44low (naı̈ve CD8 T cell, TN), CD62L
high,
CD44high, (central memory CD8 T cell, TCM), CD62L
low,
CD44high (effector memory CD8 T cells, TEM), and CD62L
low,
CD44low (acute/activated effector CD8 T cell, TAE) [51,52].
Within the spleen, we observed a significant increase in proportion
of CD8 TN cells (p = 0.0185) with a decrease in proportion of TEM
(p = 0.0021) and TAE (p = 0.0021) subsets, but no change in TCM
proportion (Fig. 10A–E). Similar alterations were observed in the
MLN. Mesenteric lymph node CD8 T cells in meth-treated mice
showed a significant increase in proportion of CD8 TN cells
(p,0.0001) with a decrease in proportion of TEM (p,0.0001), TAE
(0 = 0.0011), and TCM subsets (p = 0.0029; Fig. 11 A–E). From
these results, it appears that meth also negatively impacts the
accumulation of antigen-experienced CD8 T cells, similar to what
was observed in CD4 T cells.
Meth treatment results in decreased numbers of KLRG1+
CD8 T cells in the MLN. KLRG1 is expressed by effector CD8
T cells [53], and we postulated that meth’s disruption of antigen
presenting pathways and T cell activation would also effect the
profile of this marker of CD8 T cell activation. Interestingly, we
observed a significant decrease in KLRG1-expressing CD8 T cells
(p,0.0001) in the MLN (Figure 12 A), yet we observed no
difference in KLRG1 expression by CD8 T cells in the spleen
(data not shown). This reduction in the MLN adds further
evidence to support the notion that meth reduces specific effector
T cells and may promote weakened immunity.
Discussion
Meth Decreases the Abundance of Splenic Innate
Leukocytes
Previous studies have suggested meth has the potential to
disrupt immune homeostasis and leave the user more susceptible
to pathogenic challenge. With meth impacting the function of NK
cells and antigen-presenting cells (APCs), a basis of innate
immunity becomes weakened, and consequent and appropriate
adaptive responses by T and B cells are less likely. In this study, we
observed an overall decrease in both proportion and number of
splenic NK cells, DCs, and Gr-1high monocytes/macrophages.
Figure 5. Meth reduces proportions of CD62Llow, CD44high splenic CD4 T cells and these cells exhibit lower CD27 expression. Splenic
CD4 T cells were examined after meth treatment to determine if meth alters surface phenotypes suggesting activation/antigen experience and
effector status. A. Representative gating showing CD62L and CD44 on CD4 T cells. B. Meth causes a reduction in proportion of CD44high, CD62Llow
CD4 T cells. C. CD27 expression by CD44high, CD62Llow CD4 T cells. D. CD44high, CD62Llow CD4 T cells from meth treated animals exhibit a lower
proportion of cells expressing CD27 at a high level. **p,0.01, ***p,0.001 calculated by Mann-Whitney U Test. Bars represent mean. Data are from 2
experiments of 5 animals per treatment group per experiment.
doi:10.1371/journal.pone.0049897.g005
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Meth-induced leukopenia had been previously reported by Saito
et al. [37], who noted reduced numbers of leukocytes in the blood
of male Slc:ddY mice at 1, 4, 24, and 48 hours after meth
treatment, but did not determine which subsets were impacted by
meth. Furthermore, our results showing no difference in splenic T
and B cell proportion after meth treatment are in agreement with
the findings of Wey et al. [31], who analyzed splenocytes from
meth-treated BALB/c mice for proportion of B220, CD4 and
CD8-expressing cells. While the effect of meth of promoting
apoptosis [28,39] may explain some of this reduction in cell
number, it would also raise the question as to why certain subsets
remain relatively unchanged after meth exposure.
Figure 6. Meth causes reduced proportions of alternatively spliced CD4 T cells among the splenic CD62Lhigh compartment.Meth and
control mice were analyzed for surface expression of CD45RB and CD44 on the CD62Lhigh subset. CD45RB expression is downregulated upon antigen
experience and can be used to gauge activation levels of CD4 T cells. A. CD45RB and CD44 on CD62Lhigh splenic CD4 T cells. B–D. Meth-treated
animals had a higher proportion of CD45RBhigh, CD44low CD4 T cells compared to controls. Meth-treated animals also exhibited lower proportions of
CD45RBlow, CD44low and CD45RBlow, CD44highsubsets compared to controls. ***p,0.001 calculated by Mann-Whitney U Test. Bars represent mean.
Data are from 2 experiments of 5 animals per treatment group per experiment.
doi:10.1371/journal.pone.0049897.g006
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Figure 7. Meth treatment causes a reduction in proportion of CD62Llow, CD44high CD4 T cells in the mesenteric lymph node (MLN).
MLN CD4 T cells were labeled with CD62L and CD44 to determine proportions of antigen-experienced cells. A. CD62L and CD44 on MLN CD4 T cells
from meth and vehicle treated animals. B. Meth causes a reduction in proportion of CD44high, CD62Llow CD4 T cells in the MLN. **p,0.01 calculated
by Mann-Whitney U Test. Bars represent mean. Data are from 2 experiments of 5 animals per treatment group per experiment.
doi:10.1371/journal.pone.0049897.g007
Figure 8. Increased expression of CD150 on CD226+ CD4 T cells after meth treatment. We examined the expression of the costimulatory
markers CD150 and CD226 by splenic CD4 T cells after meth treatment. A. Representative gating and histogram showing selection of CD226+ CD4 T
cells and increased expression of CD150 by meth treated animals compared to control. Red represents a meth-treated animal, black is vehicle-treated
animal, and grey is the isotype control. B. CD226+ CD4 T cells from meth treated animals express higher levels of CD150 than those from control
animals. Protein expression was calculated using mean fluorescence intensity (MFI). ***p,0.001 calculated by Mann-Whitney U Test. Error bars
represent SEM. Data are from 2 experiments of 5 animals per treatment group per experiment.
doi:10.1371/journal.pone.0049897.g008
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The findings of Saito et al. showing leukocyte deficiencies in
blood and our observed reductions of myeloid populations within
the spleen may suggest a sensitivity to meth in the bone marrow,
a lipid-rich environment that may store meth and have
detrimental effects on bone marrow-derived leukocyte subsets. It
is known that meth is lipophilic and can accumulate in solid tissue
[12,13], and it has been reported that meth can persist in bone
marrow [54–56]. Additionally, In et al. [30] reported reduced
granulocyte-macrophage colony formation in GM-CSF-treated
cultures of bone marrow harvested from meth-treated CD-1 mice.
For these reasons, it would be meaningful to perform additional
investigations on the effects of meth on haematopoesis and the
seeming imperviousness to meth by B cells, neutrophils, and Gr-
1low monocytes/macrophages compared to other bone marrow-
derived subsets.
The immunological roles of Gr-1(Ly-6C)low and Gr-1(Ly-
6C)high monocytes/macrophages are not completely clear, but it
has been shown that Ly-6Clow monocytes appear to be a more
stable, tissue resident and endothelium-monitoring population
capable of macrophage and DC differentiation, while Ly-6Chigh
monocytes tend to home to areas of inflammation and mature to
inflammatory DCs and macrophages [57]. Our observation of
reduced splenic Gr-1(Ly-6C)high monocytes/macrophages fits well
with the reduced number of peritoneal macrophages after meth
exposure reported by In et al. [32]. In their study, they utilized the
intraperitoneal thioglycolate injection model of inflammation to
promote macrophage accumulation in the peritoneum. This
model has been shown to cause the migration of Ly-6Chigh (but
not Ly-6Clow) monocytes to the peritoneum [57], where they
ultimately mature to macrophage. The noted deficiencies in
peritoneal macrophages correlates with our observation of reduced
numbers of splenic precursors to this population. Indeed, the
spleen has been shown to be a significant reservoir of mature
monocytes and upon inflammatory signaling, to exhibit substantial
decreases in monocyte numbers as cells emigrate [42].
Figure 9. Meth promotes the expansion of splenic KLRG1+, FoxP32 CD4 T cells. Meth-treated animals possessed an expansion of KLRG1+
CD4 T cells within the spleen. These cells were CD44high and negative/low for FoxP3, CD25, CD62L, NKG2D, and CD45RB. A. Representative gating
showing significant expansion of splenic KLRG1+, FoxP32 CD4 T cells among the CD44high, CD45RBlow compartment with relatively unchanged
proportions of FoxP3-expressing subsets after meth treatment. B and C. Proportion and absolute number of KLRG1+, FoxP32 CD4 cells are increased
with meth. ***p,0.001 calculated by Mann-Whitney U Test. Bars represent mean. Data are from 2 experiments of 5 animals per treatment group per
experiment.
doi:10.1371/journal.pone.0049897.g009
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Perturbed Gr-1low Monocytes/macrophages may be
Responding to Meth-induced Cytotoxicity and Exhibiting
a Tolerogenic Function
In addition to alterations in splenic abundance, our results
indicate that the Gr-1(Ly-6C)high and Gr-1(Ly-6C)low monocyte/
macrophage populations are unequally affected by meth in terms
of activation. While we observed no difference in CD86 and CD80
expression by Gr-1(Ly6C)high monocytes/macrophages, we did
observe a significant increase in CD80 expression by Gr-1(Ly-
6C)low monocytes/macrophages, with no change in their CD86
expression. In addition to their role in vascular repair and
monitoring [58], Ly6Clow monocytes/macrophages have been
reported to operate as phagocytes, capable of engulfing debris
from dead cells and ultimately promoting T cell proliferation [59]
or self tolerance [60]. If meth is capable of inducing increased rates
of apoptosis as suggested by Potula et al. [28] and Iwasa et al.
[39], perhaps this population of monocytes/macrophages is
responding to an accumulation of dead material and maturing
to promote tolerance. Indeed, CD80 has been shown to bind
PDL-1 [61,62] and this interaction results in reduced rates of
proliferation among T cells [61,63], suggesting a tolerogenic
function of CD80 in addition to it’s known role in costimulation
[64]. Although CD80-CTLA-4 interactions have also been
proposed to terminate effector T cell responses in the periphery
[44], our data do not lend themselves to this interpretation. The
Ly-6Clow monocytes/macrophages in our study are MHC II2,
thus they are not presenting antigen in this manner and therefore
are unlikely to be involved in specific TCR-MHC II interactions.
Furthermore, the only expansion of T cells we observed was within
the CD4 compartment, suggesting MHC II dependency and
providing little evidence for cross presentation.
Accumulation and removal of apoptotic cells may also explain
our observed decrease in CD11b expression on Ly-6Clow
monocytes/macrophages. A recent report by Schif-Zuck et al.
[65] has described a decrease in CD11b expression on ‘‘satiated’’
macrophages resulting from iC3b directed internalization of
apoptotic cells. Although work by Talloczy et al. [33] and
Martinez et al. [34] has suggested reduced phagocytic efficacy
due to the basic properties of meth impacting with the acidic
endosome of macrophages, findings that suggest reduced antigen-
presentation effectiveness and activation, their results did not
suggest eliminated antigen processing and internalization capabil-
ities, rather, attenuated, and therefore are not in disagreement with
our findings.
Meth-induced Alterations in NK Cell Proportion and
Number Suggest Functional Deficiencies
The fundamental roles performed by NK cells in viral immunity
[66], tumor surveillance [67], and guiding the adaptive immune
response have been revealed [68]. Consequently, a deficiency in
NK cell number as well as NK cell function may lead to weakened
immunity. Our observation of an increased proportion of
terminally differentiated NK cells corresponds with previous
Figure 10. Meth-treated animals exhibit a greater proportion of naı̈ve phenotype CD8 T cells and reduced proportions of antigen-
experienced subsets within the spleen. Splenic CD8 T cells were labeled with CD62L and CD44 and classified into 4 groups according the
expression of these two proteins: CD62Lhigh, CD44low (Naı̈ve CD8 T cell, TN), CD62L
high, CD44high, (central memory CD8 T cell, TCM), CD62L
low, CD44high
(effector memory CD8 T cells, TEM), and CD62L
low, CD44low (acute effector CD8 T cell, TAE). A. Gating showing CD44 and CD62L expression by splenic
CD8 T cells. B–E. After meth treatment, the TN compartment is increased in proportion, while the TAE and TEM showed a decrease in proportion and
TCM appeared unchanged. *p,0.05, **p,0.01 calculated by Mann-Whitney U Test. Bars represent mean. Data are from 2 experiments of 5 animals
per treatment group per experiment.
doi:10.1371/journal.pone.0049897.g010
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reports suggesting altered activation levels of NK cells after meth
exposure [30,35]. KLRG1 expression by NK cells is almost
exclusively restricted to the CD11bhigh, CD27low subset
[45,46,69], a group that exhibits lower levels of homeostatic
proliferation [45,69] and possesses lower levels of cytotoxicity than
its CD27high counterpart [45]. KLRG1-expressing NK cells have
also been shown to produce lower levels of IFN-c than KLRG12
NK cells [70]. Our data suggest that meth causes a shift in the NK
cell compartment, with a marked reduction in CD27high,
KLRG12 NK cells after meth treatment. This shift leaves the
majority of NK cells in periphery with a phenotype suggesting
lower responsiveness and effectiveness, a dangerous combination
considering the importance of NK cells during viral infections and
the increased susceptibility of meth users to several viruses.
Figure 11. CD8 T cells from the mesenteric lymph node (MLN) also show reductions in proportion of antigen-experienced subsets
with an increase in the naı̈ve compartment. Mesenteric lymph node CD8 T cells were labeled with CD62L and CD44 and classified as in Fig. 10.
A. Gating showing CD44 and CD62L expression by MLN CD8 T cells. B–E. After meth treatment, the TN compartment is increased in proportion, while
the TAE, TEM, and TCM compartments all revealed a decrease in proportion. **p,0.01, ***p,0.001 calculated by Mann-Whitney U Test. Bars represent
mean. Data are from 2 experiments of 5 animals per treatment group per experiment.
doi:10.1371/journal.pone.0049897.g011
Figure 12. Meth causes a reduced proportion and number of KLGR1+ CD8 T cells in the MLN. CD8 T cells were labeled with KLRG1 to
investigate whether meth impacts subsets of antigen-experienced CD8 T cells. A. The proportion and number of CD8 T cells expressing KLRG1 in the
MLN is reduced after meth treatment. *p,0.01, ***p,0.001 calculated by Mann-Whitney U Test. Bars represent mean. Data are from 2 experiments of
5 animals per treatment group per experiment.
doi:10.1371/journal.pone.0049897.g012
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T Cells Exhibit Signs of Suppression as well as Activation
After Meth Treatment
We have observed that meth causes a reduction of activated/
antigen-experienced CD4 and CD8 T cells. We noted substantial
decreases in proportion of CD44high, CD62Llow CD4 T cells after
meth treatment and within this population, we observed a decrease
in proportion of cells expressing CD27. Combined, these results
suggest a decrease in CD4 T cell activation perhaps due to
diminished antigen presentation as well as a polarization to short-
lived status, as CD27 expression has been associated with longevity
in T cells [71].
Within the CD62L+ subset of CD4 T cells, we observed
a decrease in proportion CD45RBlow/CD44low, and CD45RBlow/
CD44high cells, with an increased proportion of CD45RBhigh/
CD44low cells. While the majority of naı̈ve splenic T cells express
CD45RB, after antigen experience these cells will undergo
alternate exon splicing and downregulate CD45RB [72]. The
observed deficiencies in CD45RB downregulation may be induced
by reduced APC effectiveness as well as the reduced number of
DCs observed in our experiment. Alternatively, meth may directly
obstruct CD45 exon splicing in some fashion. An additional
possibility is that meth promotes increased thymic output or
enhanced proliferation by naı̈ve subsets within the spleen.
However, our data do not reveal an increase in splenic T cell
number, nor did we find an altered CD4:CD8 ratio after meth
treatment. Although we did not investigate the thymus in our
study, it is probable that meth also accumulates within thymic
tissue and may impact thymic selection and output. Supporting
this notion, Iwasa et al. [39] observed an increased proportion of
apoptotic cells in the thymus after a single injection of meth, while
In et al. [30] noted an increase in proportion of CD4 T cells in the
thymus with decreases in proportion CD8 and double positive
(DP) T cells accompanied with reduced thymic weight after meth
use, findings which justify further investigations of the effects of
meth on the thymus.
CD8 T cell activation patterns were similarly affected as those of
CD4 T cells. We observed reduced proportions of effector
memory (TEM) and acute effector (TAE) CD8 T cells subsets in
the spleen and reduced proportions of TEM, central memory
(TCM), and TAE subsets in the MLN, again suggesting either
decreased antigen presentation and/or increased cell death among
these reduced populations. These overall decreases in CD4 and
CD8 T cell activation may be highly detrimental during the host’s
response to pathogenic challenge. Considering that meth users are
at increased risk for HIV and other viral infections, suppression of
the immune adaptive response would be expected to lead to
exacerbated infections. In agreement with this reasoning, meth use
accompanying HIV has been associated with increased viral loads
in human subjects [73].
Although our investigations revealed signs of suppression of the
CD4 and CD8 T cell response, we did observe associations
suggesting activation, namely, increased CD150 expression by
Figure 13. Methamphetamine impacts the innate and adaptive arms of immunity. Summary of the effects of methamphetamine on
immune cell subsets based upon the observations in this report.
doi:10.1371/journal.pone.0049897.g013
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CD226+ CD4 T cells and an expansion of KLRG1+ CD4 T cells.
CD150 upregulation by T cells has been observed after
concanavalin A [47] and anti-CD3 [74] stimulation, and CD150
costimulation with anti-CD3 antibodies induced increased IFN-c
prodution and proliferation compared to anti-CD3 antibody
treatment alone [47]. In our analysis of the splenic CD4 T cell
compartment after meth treatment, we noted an increase in
CD150 expression among CD226+ CD4 T cells that are also
CD44high and CD62Llow. This is an interesting finding considering
that overall CD44high,CD62Llow numbers were decreased with
meth use, thus suggesting a specific subset(s) of unknown TCR
specificity is somehow activated by meth, while others are
diminished.
Killer cell lectin-like receptor G1 (KLRG1) is an inhibitory C-
type lectin receptor that binds to E, N, and R cadherins [75,76]
and we observed alterations in KLRG1 expression by NK cells
and CD4 and CD8 T cells after meth treatment. Interestingly, we
noted an expansion of KLRG1+ FoxP32 CD4 T cells that appears
surprising in the midst of signs of several signs of immune
suppression. Increased KLRG1+ CD4 T cells have been reported
after Toxoplasma gondii infection [70] and Mycobacterium tuberculosis
infection [77], while KLRG1+ CD4 T cells were found to be
unresponsive to TCR-induced proliferation [50] and produced
high levels of IFN-c and TNF-a after peptide stimulation [77].
Beyersdorf et al. [50] also observed that a portion of FoxP3+ CD4
T cells coexpressed KLRG1 and CD152, were CD25+/2, and that
KLRG1+, CD25+/2 CD4 T cells were capable of reducing cellular
proliferation of anti-CD3 stimulated naı̈ve CD4 T cells in the
presence of APC, as well as limiting H3 thymidine uptake by
TCR-stimulated naı̈ve CD4 T cells. From these studies, we can
conclude that there are at least two main populations of KLRG1+
CD4 T cells in mice: one which represents a terminally
differentiated effector, and another which is a potent TREG.
While we did observe KLRG1+ expression amongst FoxP3+ CD4
T cells and these cells were CD25+/2, we did not find a difference
in proportion or number of any FoxP3-expressing CD4 T cell
subset after meth treatment. Phenotypically, our KLRG1+ CD4 T
cell subset fits into an effector/memory phenotype, being
CD62L2, CD45RBlow, CD252, FoxP32 and CD44high. However,
future studies must be conducted to determine the functional
attributes of this population and to determine its Th status. 1558–
1565.
Conclusions
Our results demonstrate that meth impacts several leukocyte
populations (Fig. 13). Indeed, meth’s role in inducing apoptosis
and inhibiting APC function may have tremendous effects on T
cell memory populations as well as on T cell activation, as our
results and those of others have suggested. Furthermore, the
combined effects of a decrease of Gr-1high monocytes/macro-
phages, DCs, and NK cell numbers, with a proportional increase
of a less-responsive NK cell subset may leave the user less able to
initiate a sufficient immune response and ultimately reduce the
effectiveness of the adaptive response. Although our data reveal
specific descriptive alterations induced by meth and suggest
a reduced ability to respond efficiently to pathogens, additional
investigations must focus on how the innate and adaptive arms are
impacted in the face of viral and bacterial challenge concurrent
with meth exposure. As meth addicts are at risk for increased rates
of sexually transmitted diseases (STDs) and blood borne pathogens
due to behavioral responses and drug administration routes, these
investigations would be meaningful in revealing which mechan-
isms promote increased susceptibility to infections as suggested by
this work and previous studies.
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